Saladax Biomedical Announces U.S. Launch of MyImatinib Chemotherapy Exposure Optimization Test
Saladax Biomedical, Inc., a Bethlehem, PA-based company that develops and commercializes diagnostic tests, is launching a new diagnostic test called MyImatinib, which determines a patient’s exposure to chemotherapy in an effort to improve and personalize dosing. The tests provide oncologists with specific information about each patient’s exposure to chemotherapy, helping the doctor make decisions on drug dose adjustments, improving the therapy’s effectiveness and limiting potential side effects. Kevin Harter, president and CEO of Saladax Biomedical, reports that a company analysis found 50 percent of patients are not receiving an optimal chemotherapy dosage, and these tests should help improve that. Learn more about Saladax Biomedical.